Gilead Sciences (GILD) Research & Development (2009 - 2026)

Gilead Sciences has reported Research & Development for 18 years, with the latest figure at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 0.51% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.8 billion (changed 0.47% YoY), and the FY2025 full-year result was $5.8 billion, down 1.83% from the prior year.
• Research & Development for Q1 2026 stood at $1.4 billion, down from $1.6 billion in the prior quarter.
• The five-year high for Research & Development was $1.6 billion in Q4 2024, with the low at $1.1 billion in Q2 2022.
• Historically, Research & Development has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
• Annual changes were most pronounced in 2023 — Research & Development rose 27.68% — and 2025, when it decreased 9.28%.
• Gilead Sciences' Research & Development stood at $1.5 billion in 2022, then slipped by 9.04% to $1.4 billion in 2023, then climbed by 16.55% to $1.6 billion in 2024, then slipped by 3.47% to $1.6 billion in 2025, then retreated by 13.38% to $1.4 billion in 2026.
• The last three Research & Development figures came in at $1.4 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.